Recombinant Anti-CD89 x Anti-EGFR Bispecific Antibody (scFv-IgG) is formed by an IgG and two scFv fragments. The scFvs from an anti-CD89 antibody variable domain are respectively connected to the N terminus of the anti-EGFR IgG heavy chains or light chains to form scFv-(H)IgG or scFv-(L)IgG. It is a type of appended IgGs and has 2+2 antigen-binding valency. This BsAb can retarget macrophages to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Non-small cell lung cancer (NSCLC); Solid tumors therapy.